Lazard Asset Management’s Cytokinetics CYTK Stock Holding History

Lazard Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Hold	1,369	–	–	﹤0.01%	1733
2026 Q1	$90.2K	Buy	+1,369	New	+$87K	﹤0.01%	1735
2025 Q3	–	Sell	-2,055	Closed	-$67K	–	1927
2025 Q2	$67K	Sell	2,055 -34,113	-94%	-$1.19M	﹤0.01%	1956
2025 Q1	$1.45M	Buy	+36,168	New	+$1.66M	﹤0.01%	1069
2023 Q3	–	Sell	-24,716	Closed	-$806K	–	2314
2023 Q2	$806K	Sell	24,716 -10,292	-29%	-$381K	﹤0.01%	1028
2023 Q1	$1.23M	Sell	35,008 -4,120	-11%	-$168K	﹤0.01%	987
2022 Q4	$1.79M	Sell	39,128 -12,017	-23%	-$517K	﹤0.01%	918
2022 Q3	$2.48M	Sell	51,145 -1,648,281	-97%	-$79.3M	﹤0.01%	843
2022 Q2	$66.8M	Buy	1,699,426 +1,697,631	+94,576%	+$68.3M	0.09%	196
2022 Q1	$66K	Buy	1,795 +1,695	+1,695%	+$60.2K	﹤0.01%	1599
2021 Q4	$4K	Hold	100	–	–	﹤0.01%	2178
2021 Q3	$3K	Buy	+100	New	+$2.94K	﹤0.01%	2107
2021 Q2	–	Sell	-114,478	Closed	-$2.66M	–	1981
2021 Q1	$2.66M	Sell	114,478 -28,921	-20%	-$618K	﹤0.01%	754
2020 Q4	$2.98M	Sell	143,399 -118,115	-45%	-$2.16M	﹤0.01%	726
2020 Q3	$5.66M	Sell	261,514 -8,076	-3%	-$189K	0.01%	587
2020 Q2	$6.35M	Buy	+269,590	New	+$5.06M	0.01%	533

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's CYTK Position: Q2 2026 in Review

Lazard Asset Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1,369 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1733.

Lazard Asset Management first reported a position in CYTK in Q2 2020 and has held it in 16 quarters since. The position peaked at $66.8M in Q2 2022. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Lazard Asset Management held 1,369 shares of Cytokinetics worth $117K as of Q2 2026.
Lazard Asset Management left its Cytokinetics share count unchanged in Q2 2026.
Cytokinetics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1733 holding.
Lazard Asset Management first reported a position in Cytokinetics in Q2 2020 and has held it in 16 quarters since.
Lazard Asset Management's Cytokinetics position peaked at $66.8M in Q2 2022.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.